PMID- 35547005
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220716
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Serum Lipocalin-2 Levels Are Increased and Independently Associated With 
      Early-Stage Renal Damage and Carotid Atherosclerotic Plaque in Patients With 
      T2DM.
PG  - 855616
LID - 10.3389/fendo.2022.855616 [doi]
LID - 855616
AB  - OBJECTIVES: Diabetic nephropathy (DN), one of the major complications of diabetes 
      mellitus, is the major cause of end-stage renal failure that finally increases 
      the risk of cardiovascular disease and mortality. The aim of this study is to 
      explore the relationship between serum lipocalin-2 (LCN-2) levels and DN and 
      carotid atherosclerotic plaque (CAP) in patients with type 2 diabetes mellitus 
      (T2DM). METHODS: We have performed a prospective study of 749 T2DM patients with 
      or without DN. Blood samples were collected and used to test serum LCN-2 levels, 
      renal function, as well as biochemical parameters. CAP in these subjects was 
      determined by ultrasonography. RESULTS: In these 749 subjects with T2DM, an 
      increased morbidity of CAP was observed in T2DM patients with DN as compared with 
      those without this complication (P < 0.05). Interestingly, serum LCN-2 levels 
      were significantly increased in T2DM patients with DN or CAP compared with T2DM 
      alone [97.71 (71.49-130.13) vs. 77.29 (58.83-115.05) ng/ml, P < 0.001]. In 
      addition, serum LCN-2 levels in T2DM patients with DN and CAP were significantly 
      higher than that of T2DM patients with DN or CAP [131.37 (101.43-182.04) vs. 
      97.71(71.49-130.13) ng/ml, P < 0.001]. Furthermore, serum LCN-2 levels were 
      positively correlated with hemoglobin A1c, systolic blood pressure, hypertension, 
      CAP, and DN, as well as renal function factors including uric acid, creatinine, 
      the estimated glomerular filtration rate, and urinary albumin-to-creatinine 
      ratio, respectively (P < 0.05), but negatively correlated with HDL-c (P < 0.05). 
      The multinomial logistic regression analysis showed that serum LCN-2 was 
      independently associated with DN and CAP in patients with T2DM after the 
      adjustment for risk factors (P < 0.001). CONCLUSIONS: Early-stage renal damage is 
      a risk factor associated with the incidence of CAP in patients with T2DM. Serum 
      LCN-2 is significantly increased and associated with early-stage renal damage and 
      the incidence of CAP in patients with T2DM.
CI  - Copyright (c) 2022 Gan, Zheng, Yu, Zhang, Xie, Shi, Yu, Yan, Lin and Yang.
FAU - Gan, Jing
AU  - Gan J
AD  - The 2nd Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
FAU - Zheng, Yu
AU  - Zheng Y
AD  - The 2nd Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
FAU - Yu, Qiongli
AU  - Yu Q
AD  - School of Pharmaceutical College, Wenzhou Medical University, Wenzhou, China.
FAU - Zhang, Yingchao
AU  - Zhang Y
AD  - School of Pharmaceutical College, Wenzhou Medical University, Wenzhou, China.
FAU - Xie, Wei
AU  - Xie W
AD  - School of Pharmaceutical College, Wenzhou Medical University, Wenzhou, China.
FAU - Shi, Yaru
AU  - Shi Y
AD  - School of Pharmaceutical College, Wenzhou Medical University, Wenzhou, China.
FAU - Yu, Ning
AU  - Yu N
AD  - School of Pharmaceutical College, Wenzhou Medical University, Wenzhou, China.
FAU - Yan, Yu
AU  - Yan Y
AD  - The 2nd Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
FAU - Lin, Zhuofeng
AU  - Lin Z
AD  - School of Pharmaceutical College, Wenzhou Medical University, Wenzhou, China.
AD  - The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
AD  - Laboratory Animal Center of Wenzhou Medical University, Wenzhou, China.
FAU - Yang, Hong
AU  - Yang H
AD  - The 3rd Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220425
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Lipocalin-2)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Creatinine
MH  - *Diabetes Mellitus, Type 2
MH  - *Diabetic Nephropathies/etiology
MH  - Female
MH  - Humans
MH  - Kidney/physiology
MH  - Lipocalin-2
MH  - Male
MH  - *Plaque, Atherosclerotic/complications
MH  - Prospective Studies
PMC - PMC9081837
OTO - NOTNLM
OT  - cardiovascular disease
OT  - carotid atherosclerotic plaque
OT  - early-stage renal damage
OT  - lipocalin-2
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/14 06:00
MHDA- 2022/05/18 06:00
PMCR- 2022/01/01
CRDT- 2022/05/13 11:08
PHST- 2022/01/15 00:00 [received]
PHST- 2022/03/15 00:00 [accepted]
PHST- 2022/05/13 11:08 [entrez]
PHST- 2022/05/14 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.855616 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Apr 25;13:855616. doi: 
      10.3389/fendo.2022.855616. eCollection 2022.